Apr 20, 2021 • 8:05 am EDT Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
Mar 30, 2021 • 8:05 am EDT Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Mar 15, 2021 • 7:05 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
Mar 8, 2021 • 8:05 am EST Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
Jan 20, 2021 • 8:05 am EST Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
Nov 12, 2020 • 8:05 am EST Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Nov 10, 2020 • 7:05 am EST Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
Nov 9, 2020 • 8:05 am EST Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis